Latest United States News

Adisyn says the USPTO has allowed its third US patent application, extending its graphene deposition claims from metallic surfaces to non-metallic semiconductor materials. The allowed claims also include low-temperature processing and in-process quality checks, although commercial adoption remains unconfirmed.

Victory Metals has secured a 2,006-hectare mining lease for its North Stanmore heavy rare earths project in Western Australia. The grant removes a key tenure hurdle, but technical studies, approvals, offtake agreements and financing still stand between the project and a development decision.

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

Resolution Minerals has finished its largest-ever exploration program at the Horse Heaven project in Idaho, drilling 42 diamond holes across 12,236 metres. The work sets up a substantial run of gold, tungsten and multi-element assay results, but the completed program has not yet produced new assay data in this announcement.

QEM has ranked the Vaught-Peck prospect as the leading target at its newly acquired Garden Valley project in Idaho after reviewing historical records of columbite, samarskite and other rare-metal minerals. The opportunity remains prospective rather than proven, with no modern drilling, assays or resource estimate yet reported.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Optiscan Imaging has reached an 84-case milestone in its live digital pathology study with Australian Clinical Labs, testing the InForm platform across a broad range of tissue types and disease settings. The data may support future regulatory submissions and commercial discussions, but the announcement does not disclose diagnostic accuracy metrics or regulatory approval.

VHM has taken Goschen from a permitted project to a more financeable development, with Iluka committing to buy all planned rare earth concentrate and providing A$40 million in convertible note funding. The company remains pre-revenue, has not made a Final Investment Decision and will need further funding before construction can begin.

OD6 Metals has extended its Rocket-Big Jim-Spar fluorspar corridor at Quinn in Nevada to approximately 700 metres, with six surface samples returning at least 97% CaF₂ and three reaching 99.9%. The results expand the project’s high-grade story, but remain based on selective rock-chip sampling rather than drilling.

Sovereign Metals says a simple add-on circuit at its Malawi project could generate US$722 million of pre-tax value from monazite by-product recovery. The opportunity is commercially striking, but remains a preliminary scoping result dependent on further testwork, approvals, funding and customer qualification.

Olympio Metals has begun field exploration across its Jacknife and Raven silver projects in the United States, with drilling at Jacknife expected to start imminently. A replacement announcement also strengthens the company’s description of a historical foreign estimate, while making clear that the estimate remains non-JORC and requires fresh verification.